If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> RHEUMATOLOGY<br /> ISSN 2056-6395 Vol 5.1 • July 2018 • europeanmedical-journal.com<br /> INSIDE<br /> Review of<br /> EULAR 2018<br /> Amsterdam, Netherlands<br /> Contents<br /> EDITORIAL BOARD 4<br /> WELCOME 7<br /> FOREWORD 8<br /> 01 CONGRESS REVIEW<br /> Review of EULAR 2018, held in Amsterdam, Netherlands, 10<br /> 13th–16th June 2018<br /> 02 INTERVIEWS WITH EMJ RHEUMATOLOGY EDITORIAL BOARD<br /> Dr Ian C. Chikanza 26<br /> Dr Christakis C<a title="EMJ Rheumatology 5.1 2018 page 1" href="http://viewer.zmags.com/publication/915cc038?page=1"> RHEUMATOLOGY ISSN 2056-6395 </a> <a title="EMJ Rheumatology 5.1 2018 page 2" href="http://viewer.zmags.com/publication/915cc038?page=2"> Contents EDITORIAL BOARD </a> <a title="EMJ Rheumatology 5.1 2018 page 3" href="http://viewer.zmags.com/publication/915cc038?page=3"> "The field of rheumatology is advancing at a blist</a> <a title="EMJ Rheumatology 5.1 2018 page 4" href="http://viewer.zmags.com/publication/915cc038?page=4"> Editorial Board Editor-in-Chief Dr Ian C. Chikanz</a> <a title="EMJ Rheumatology 5.1 2018 page 5" href="http://viewer.zmags.com/publication/915cc038?page=5"> Aims and Scope The European Medical Journal (EMJ)</a> <a title="EMJ Rheumatology 5.1 2018 page 6" href="http://viewer.zmags.com/publication/915cc038?page=6"> EMJ Rheumatology Chief Executive Officer Spencer </a> <a title="EMJ Rheumatology 5.1 2018 page 7" href="http://viewer.zmags.com/publication/915cc038?page=7"> Welcome It is with great pride that I present to </a> <a title="EMJ Rheumatology 5.1 2018 page 8" href="http://viewer.zmags.com/publication/915cc038?page=8"> Foreword A warm welcome to this year’s stimulatin</a> <a title="EMJ Rheumatology 5.1 2018 page 9" href="http://viewer.zmags.com/publication/915cc038?page=9"> mediators is presented within. This opens up othe</a> <a title="EMJ Rheumatology 5.1 2018 page 10" href="http://viewer.zmags.com/publication/915cc038?page=10"> </a> <a title="EMJ Rheumatology 5.1 2018 page 11" href="http://viewer.zmags.com/publication/915cc038?page=11"> Congress Review Review of the 19th EU</a> <a title="EMJ Rheumatology 5.1 2018 page 12" href="http://viewer.zmags.com/publication/915cc038?page=12"> organisers to always improve the congress year af</a> <a title="EMJ Rheumatology 5.1 2018 page 13" href="http://viewer.zmags.com/publication/915cc038?page=13"> Comparison of Malignancy Rates Between Tocilizuma</a> <a title="EMJ Rheumatology 5.1 2018 page 14" href="http://viewer.zmags.com/publication/915cc038?page=14"> Intensive Treatment for Rheumatoid Arthritis Prov</a> <a title="EMJ Rheumatology 5.1 2018 page 15" href="http://viewer.zmags.com/publication/915cc038?page=15"> Zoledronic Acid Treatment Shows Promise for Mild </a> <a title="EMJ Rheumatology 5.1 2018 page 16" href="http://viewer.zmags.com/publication/915cc038?page=16"> Canakinumab Cuts Gout Flare Rates in Patients wit</a> <a title="EMJ Rheumatology 5.1 2018 page 17" href="http://viewer.zmags.com/publication/915cc038?page=17"> “Our results are very encouraging and reinforce t</a> <a title="EMJ Rheumatology 5.1 2018 page 18" href="http://viewer.zmags.com/publication/915cc038?page=18"> Focussing on RA-risk individuals who have sp</a> <a title="EMJ Rheumatology 5.1 2018 page 19" href="http://viewer.zmags.com/publication/915cc038?page=19"> The researchers conducted a retrospective</a> <a title="EMJ Rheumatology 5.1 2018 page 20" href="http://viewer.zmags.com/publication/915cc038?page=20"> of cardiovascular risk among individuals wit</a> <a title="EMJ Rheumatology 5.1 2018 page 21" href="http://viewer.zmags.com/publication/915cc038?page=21"> This initiative supports Young PARE, a working gr</a> <a title="EMJ Rheumatology 5.1 2018 page 22" href="http://viewer.zmags.com/publication/915cc038?page=22"> Congress Feature Dr Louise Bennett Rheu</a> <a title="EMJ Rheumatology 5.1 2018 page 23" href="http://viewer.zmags.com/publication/915cc038?page=23"> locals from the islands and the tourists who come</a> <a title="EMJ Rheumatology 5.1 2018 page 24" href="http://viewer.zmags.com/publication/915cc038?page=24"> One of Rheumatosphere’s aims, along with its part</a> <a title="EMJ Rheumatology 5.1 2018 page 25" href="http://viewer.zmags.com/publication/915cc038?page=25"> Interact with us on social med</a> <a title="EMJ Rheumatology 5.1 2018 page 26" href="http://viewer.zmags.com/publication/915cc038?page=26"> Interviews Insightful interviews from members o</a> <a title="EMJ Rheumatology 5.1 2018 page 27" href="http://viewer.zmags.com/publication/915cc038?page=27"> What treatment or technology, in your opinion, ha</a> <a title="EMJ Rheumatology 5.1 2018 page 28" href="http://viewer.zmags.com/publication/915cc038?page=28"> Your research into neuroendocrine immunology of i</a> <a title="EMJ Rheumatology 5.1 2018 page 29" href="http://viewer.zmags.com/publication/915cc038?page=29"> specialities and to have multidiscipl</a> <a title="EMJ Rheumatology 5.1 2018 page 30" href="http://viewer.zmags.com/publication/915cc038?page=30"> invitation in advance to all physicians, general </a> <a title="EMJ Rheumatology 5.1 2018 page 31" href="http://viewer.zmags.com/publication/915cc038?page=31"> Dr Christakis Christodoulou University of Nicosia</a> <a title="EMJ Rheumatology 5.1 2018 page 32" href="http://viewer.zmags.com/publication/915cc038?page=32"> on a variety of practical issues in the day-to-da</a> <a title="EMJ Rheumatology 5.1 2018 page 33" href="http://viewer.zmags.com/publication/915cc038?page=33"> and of the Achilles tendon. Musculoskeletal </a> <a title="EMJ Rheumatology 5.1 2018 page 34" href="http://viewer.zmags.com/publication/915cc038?page=34"> were the main reasons I chose rheumatology as my </a> <a title="EMJ Rheumatology 5.1 2018 page 35" href="http://viewer.zmags.com/publication/915cc038?page=35"> regarding gene expression and cell-specific ge</a> <a title="EMJ Rheumatology 5.1 2018 page 36" href="http://viewer.zmags.com/publication/915cc038?page=36"> Anti-TNF in Rheumatic Diseases: Inventor</a> <a title="EMJ Rheumatology 5.1 2018 page 37" href="http://viewer.zmags.com/publication/915cc038?page=37"> Meeting Summary With an increasing number of bios</a> <a title="EMJ Rheumatology 5.1 2018 page 38" href="http://viewer.zmags.com/publication/915cc038?page=38"> Clinical parameters • ≥1 y</a> <a title="EMJ Rheumatology 5.1 2018 page 39" href="http://viewer.zmags.com/publication/915cc038?page=39"> as the correlation to the clinical finding </a> <a title="EMJ Rheumatology 5.1 2018 page 40" href="http://viewer.zmags.com/publication/915cc038?page=40"> that should be considered (Figure </a> <a title="EMJ Rheumatology 5.1 2018 page 41" href="http://viewer.zmags.com/publication/915cc038?page=41"> Prof Enck highlighted that “the nocebo effect is </a> <a title="EMJ Rheumatology 5.1 2018 page 42" href="http://viewer.zmags.com/publication/915cc038?page=42"> Reassure them that you believe they will ma</a> <a title="EMJ Rheumatology 5.1 2018 page 43" href="http://viewer.zmags.com/publication/915cc038?page=43"> the effective implementation of biosimilars i</a> <a title="EMJ Rheumatology 5.1 2018 page 44" href="http://viewer.zmags.com/publication/915cc038?page=44"> Abstract Reviews A selection of riveting revie</a> <a title="EMJ Rheumatology 5.1 2018 page 45" href="http://viewer.zmags.com/publication/915cc038?page=45"> with time incorporated as a linear spline with ch</a> <a title="EMJ Rheumatology 5.1 2018 page 46" href="http://viewer.zmags.com/publication/915cc038?page=46"> Physician Global Assessments for Dis</a> <a title="EMJ Rheumatology 5.1 2018 page 47" href="http://viewer.zmags.com/publication/915cc038?page=47"> The authors also had discordant patient global as</a> <a title="EMJ Rheumatology 5.1 2018 page 48" href="http://viewer.zmags.com/publication/915cc038?page=48"> A 2,000 1,500 1,000 sVCAM-1: concentrati</a> <a title="EMJ Rheumatology 5.1 2018 page 49" href="http://viewer.zmags.com/publication/915cc038?page=49"> identifying surrogate serum angiogenic markers of</a> <a title="EMJ Rheumatology 5.1 2018 page 50" href="http://viewer.zmags.com/publication/915cc038?page=50"> The objective of this study was to develop and im</a> <a title="EMJ Rheumatology 5.1 2018 page 51" href="http://viewer.zmags.com/publication/915cc038?page=51"> CONCLUSIONS Collaboration between several</a> <a title="EMJ Rheumatology 5.1 2018 page 52" href="http://viewer.zmags.com/publication/915cc038?page=52"> coronary artery disease were excluded. The risk o</a> <a title="EMJ Rheumatology 5.1 2018 page 53" href="http://viewer.zmags.com/publication/915cc038?page=53"> Keywords: Bone mineral density (BMD), dual-energy</a> <a title="EMJ Rheumatology 5.1 2018 page 54" href="http://viewer.zmags.com/publication/915cc038?page=54"> References 1. Rydholm M et al. Despite early</a> <a title="EMJ Rheumatology 5.1 2018 page 55" href="http://viewer.zmags.com/publication/915cc038?page=55"> plane, and a standardised US examination of </a> <a title="EMJ Rheumatology 5.1 2018 page 56" href="http://viewer.zmags.com/publication/915cc038?page=56"> Table 1: Summary of the tests performed to compar</a> <a title="EMJ Rheumatology 5.1 2018 page 57" href="http://viewer.zmags.com/publication/915cc038?page=57"> Ankylosing spondylitis (AS), a chroni</a> <a title="EMJ Rheumatology 5.1 2018 page 58" href="http://viewer.zmags.com/publication/915cc038?page=58"> B Back problems </a> <a title="EMJ Rheumatology 5.1 2018 page 59" href="http://viewer.zmags.com/publication/915cc038?page=59"> JAK Inhibitors in the Treatment Algorithm </a> <a title="EMJ Rheumatology 5.1 2018 page 60" href="http://viewer.zmags.com/publication/915cc038?page=60"> RHEUMATOID ARTHRITIS TREATMENT APPROACH IN Rheum</a> <a title="EMJ Rheumatology 5.1 2018 page 61" href="http://viewer.zmags.com/publication/915cc038?page=61"> licensed for use in RA, more recently followed by</a> <a title="EMJ Rheumatology 5.1 2018 page 62" href="http://viewer.zmags.com/publication/915cc038?page=62"> RHEUMATOID ARTHRITIS JAK INHIBITORS IN The intro</a> <a title="EMJ Rheumatology 5.1 2018 page 63" href="http://viewer.zmags.com/publication/915cc038?page=63"> the efficacy and safety of upadacitinib versus pl</a> <a title="EMJ Rheumatology 5.1 2018 page 64" href="http://viewer.zmags.com/publication/915cc038?page=64"> preferential use of the least expensive therapy a</a> <a title="EMJ Rheumatology 5.1 2018 page 65" href="http://viewer.zmags.com/publication/915cc038?page=65"> rheumatoid arthritis and systemic lupus erythemat</a> <a title="EMJ Rheumatology 5.1 2018 page 66" href="http://viewer.zmags.com/publication/915cc038?page=66"> Switching to Biosimilars in Inflammatory Rheumat</a> <a title="EMJ Rheumatology 5.1 2018 page 67" href="http://viewer.zmags.com/publication/915cc038?page=67"> INTRODUCTION Biosimilars are similar and more aff</a> <a title="EMJ Rheumatology 5.1 2018 page 68" href="http://viewer.zmags.com/publication/915cc038?page=68"> complex high-order structures and post- t</a> <a title="EMJ Rheumatology 5.1 2018 page 69" href="http://viewer.zmags.com/publication/915cc038?page=69"> INTERCHANGEABILITY AND BIOSIMILAR SWITCHING POLIC</a> <a title="EMJ Rheumatology 5.1 2018 page 70" href="http://viewer.zmags.com/publication/915cc038?page=70"> to biosimilar, and many lack appropriate control </a> <a title="EMJ Rheumatology 5.1 2018 page 71" href="http://viewer.zmags.com/publication/915cc038?page=71"> switched from reference adalimumab to SB5 at</a> <a title="EMJ Rheumatology 5.1 2018 page 72" href="http://viewer.zmags.com/publication/915cc038?page=72"> the individual studies, the cumulative results of</a> <a title="EMJ Rheumatology 5.1 2018 page 73" href="http://viewer.zmags.com/publication/915cc038?page=73"> thType&searchType=name&curl=pag- es%2Fmedicines%2</a> <a title="EMJ Rheumatology 5.1 2018 page 74" href="http://viewer.zmags.com/publication/915cc038?page=74"> efficacy, safety and immunogenicity 47. of </a> <a title="EMJ Rheumatology 5.1 2018 page 75" href="http://viewer.zmags.com/publication/915cc038?page=75"> Primary Sjögren’s Syndrome in the Elderly: Do</a> <a title="EMJ Rheumatology 5.1 2018 page 76" href="http://viewer.zmags.com/publication/915cc038?page=76"> however, B lymphocytes and the production of</a> <a title="EMJ Rheumatology 5.1 2018 page 77" href="http://viewer.zmags.com/publication/915cc038?page=77"> Table 1: Organ and system-specific symptoms of pri</a> <a title="EMJ Rheumatology 5.1 2018 page 78" href="http://viewer.zmags.com/publication/915cc038?page=78"> reduced concentration, and/or delayed excretion o</a> <a title="EMJ Rheumatology 5.1 2018 page 79" href="http://viewer.zmags.com/publication/915cc038?page=79"> Box 1: Differences in primary Sjögren’s syndrome </a> <a title="EMJ Rheumatology 5.1 2018 page 80" href="http://viewer.zmags.com/publication/915cc038?page=80"> the number of antibodies and immunological comple</a> <a title="EMJ Rheumatology 5.1 2018 page 81" href="http://viewer.zmags.com/publication/915cc038?page=81"> Study Botsios et Chebbi et Table 2: Clinical m</a> <a title="EMJ Rheumatology 5.1 2018 page 82" href="http://viewer.zmags.com/publication/915cc038?page=82"> older and younger age groups; currently, this t</a> <a title="EMJ Rheumatology 5.1 2018 page 83" href="http://viewer.zmags.com/publication/915cc038?page=83"> Cytokines and Inflammatory Mediators in Syste</a> <a title="EMJ Rheumatology 5.1 2018 page 84" href="http://viewer.zmags.com/publication/915cc038?page=84"> apoptosis of circulating cells, a defect in clear</a> <a title="EMJ Rheumatology 5.1 2018 page 85" href="http://viewer.zmags.com/publication/915cc038?page=85"> Treatment with IL-2 and G-CSF IL-10Caspase-1 </a> <a title="EMJ Rheumatology 5.1 2018 page 86" href="http://viewer.zmags.com/publication/915cc038?page=86"> Interleukin-12 and 23 The IL-12 family includes I</a> <a title="EMJ Rheumatology 5.1 2018 page 87" href="http://viewer.zmags.com/publication/915cc038?page=87"> natural killer cells, neutrophils, and astrocytes</a> <a title="EMJ Rheumatology 5.1 2018 page 88" href="http://viewer.zmags.com/publication/915cc038?page=88"> could play a role in the development of SLE and t</a> <a title="EMJ Rheumatology 5.1 2018 page 89" href="http://viewer.zmags.com/publication/915cc038?page=89"> autoantibodies.84 Administration of t</a> <a title="EMJ Rheumatology 5.1 2018 page 90" href="http://viewer.zmags.com/publication/915cc038?page=90"> (i.e., clinical subphenotypes), and some of them </a> <a title="EMJ Rheumatology 5.1 2018 page 91" href="http://viewer.zmags.com/publication/915cc038?page=91"> 34. Schorle H et al. Development and 4</a> <a title="EMJ Rheumatology 5.1 2018 page 92" href="http://viewer.zmags.com/publication/915cc038?page=92"> Rom J Intern Med. 2010;48(3):255-9. 77. Chen XQ </a> <a title="EMJ Rheumatology 5.1 2018 page 93" href="http://viewer.zmags.com/publication/915cc038?page=93"> Disease-Modifying Antirheumatic Diets: The New </a> <a title="EMJ Rheumatology 5.1 2018 page 94" href="http://viewer.zmags.com/publication/915cc038?page=94"> the authors discussed various diets and food comp</a> <a title="EMJ Rheumatology 5.1 2018 page 95" href="http://viewer.zmags.com/publication/915cc038?page=95"> activity.14 The vitamin is required by the body f</a> <a title="EMJ Rheumatology 5.1 2018 page 96" href="http://viewer.zmags.com/publication/915cc038?page=96"> However, there is limited experimental and c</a> <a title="EMJ Rheumatology 5.1 2018 page 97" href="http://viewer.zmags.com/publication/915cc038?page=97"> anti-inflammatory drugs or corticosteroids.47,4</a> <a title="EMJ Rheumatology 5.1 2018 page 98" href="http://viewer.zmags.com/publication/915cc038?page=98"> It can be inferred that RA patients must undergo </a> <a title="EMJ Rheumatology 5.1 2018 page 99" href="http://viewer.zmags.com/publication/915cc038?page=99"> 30. Al-Ali et al. Clinical evaluation of </a> <a title="EMJ Rheumatology 5.1 2018 page 100" href="http://viewer.zmags.com/publication/915cc038?page=100"> Stroke and Systemic Lupus Erythematosus: A Revie</a> <a title="EMJ Rheumatology 5.1 2018 page 101" href="http://viewer.zmags.com/publication/915cc038?page=101"> Box 1: Principal factors implicated in the higher</a> <a title="EMJ Rheumatology 5.1 2018 page 102" href="http://viewer.zmags.com/publication/915cc038?page=102"> which is considered to be among the most i</a> <a title="EMJ Rheumatology 5.1 2018 page 103" href="http://viewer.zmags.com/publication/915cc038?page=103"> atherosclerosis even after adjustment for classic</a> <a title="EMJ Rheumatology 5.1 2018 page 104" href="http://viewer.zmags.com/publication/915cc038?page=104"> branches of the anterior, middle, and posterior c</a> <a title="EMJ Rheumatology 5.1 2018 page 105" href="http://viewer.zmags.com/publication/915cc038?page=105"> different mechanisms, such as the administration </a> <a title="EMJ Rheumatology 5.1 2018 page 106" href="http://viewer.zmags.com/publication/915cc038?page=106"> the higher CSVD score compared to patients with </a> <a title="EMJ Rheumatology 5.1 2018 page 107" href="http://viewer.zmags.com/publication/915cc038?page=107"> in cultured smooth muscle cells from human aorta.</a> <a title="EMJ Rheumatology 5.1 2018 page 108" href="http://viewer.zmags.com/publication/915cc038?page=108"> Coming soon. </a> <a title="EMJ Rheumatology 5.1 2018 page 109" href="http://viewer.zmags.com/publication/915cc038?page=109"> Buyer's Guide > ABBVIE > ALPINION MEDICAL SYSTEMS</a> <a title="EMJ Rheumatology 5.1 2018 page 110" href="http://viewer.zmags.com/publication/915cc038?page=110"> Never miss an update again. J</a>